99% Savings - Buy Just @1 Rs X
Grasipar is a prescription drug, available for use as Injection. It is typically used for the treatment of Neutropenia.
The optimal dosage of Grasipar is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
Besides the aforementioned side effects, there are other adverse effects of Grasipar as well, which are listed below. Such side effects of Grasipar normally do not last long and go away once the treatment is completed. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Grasipar is Moderate for pregnant women and Moderate for women who are breastfeeding. In addition, Grasipar's effects on the liver, heart and kidney are discussed below in the Grasipar related warnings section.
Grasipar is not recommended if you suffer from certain medical conditions as it can have adverse effects. Blood Cancer are examples of such conditions. Some other conditions that can be affected by Grasipar are listed in the contraindications section below.
Drug reaction of Grasipar with other medicines has been reported. Refer to the list below for further details.
In addition to the above precautions for Grasipar, it is important to know that it is safe while driving, and is habit-forming.
Grasipar is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Infant (1 month to 2 years) |
|
Is the use of Grasipar safe for pregnant women?
Pregnant women may experience moderate side effects from Grasipar. It is best to stop taking Grasipar immediately and inform your doctor if you notice any discomfort.
Is the use of Grasipar safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Grasipar. Immediately discontinue Grasipar if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Grasipar on the Kidneys?
Grasipar may have mild side effects on the kidneys.
What is the effect of Grasipar on the Liver?
Grasipar is rarely harmful for the liver.
What is the effect of Grasipar on the Heart?
The heart can be affected by Grasipar. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart the medicine only after medical advice.
Grasipar should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Grasipar unless your doctor advises you to do so -
Is this Grasipar habit forming or addictive?
No, there is no any evidence that Grasipar is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Grasipar since it does not cause drowsiness.
Is it safe?
Yes, but consume Grasipar only on doctor's advice.
Is it able to treat mental disorders?
No, Grasipar cannot treat any kind of mental disorder.
Interaction between Food and Grasipar
Due to a lack of research, nothing can be said about the consequences of taking Grasipar together with food.
Interaction between Alcohol and Grasipar
Information about the interaction of Grasipar and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Neupogen® (Filgrastim)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 876
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 567-560